HASBROUCK HEIGHTS, N.J., March 14, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the year ended December 31, 2013, compared to $7,627,589, or $0.23 per share for same period in 2012. The decrease of the net loss for the year is attributable primarily to a reduction of stock-based compensation charges which were $307,326 in 2013 compared to $1,962,085 in 2012. The weighted average number of common shares outstanding for the year ended December 31, 2013 was 34,147,666, compared to 33,176,185 for the same period in 2012.
Help employers find you! Check out all the jobs and post your resume.
